{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:42:03Z","timestamp":1773312123141,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012616","name":"FSER","doi-asserted-by":"crossref","award":["2021-0013"],"award-info":[{"award-number":["2021-0013"]}],"id":[{"id":"10.13039\/501100012616","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03754-3","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:04:04Z","timestamp":1695715444000},"page":"1403-1414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function"],"prefix":"10.1007","volume":"56","author":[{"given":"Hina","family":"Khalid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Mazhar","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6953-9771","authenticated-orcid":false,"given":"Sergey","family":"Shityakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"3754_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5500\/wjt.v3.i2.7","volume":"3","author":"M Salvadori","year":"2013","unstructured":"Salvadori M, Bertoni E (2013) Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant 3:7","journal-title":"World J Transplant"},{"key":"3754_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","volume":"452","author":"N Knops","year":"2013","unstructured":"Knops N, Levtchenko E, van den Heuvel B, Kuypers D (2013) From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm 452:14\u201335","journal-title":"Int J Pharm"},{"key":"3754_CR3","first-page":"241","volume":"15","author":"J Kumar","year":"2017","unstructured":"Kumar J, Bridson JM, Sharma A, Halawa A (2017) Systematic review on role of mammalian target of rapamycin inhibitors as an alternative to calcineurin inhibitors in renal transplant: challenges and window to excel. Exp Clin Transplant 15:241\u2013252","journal-title":"Exp Clin Transplant"},{"key":"3754_CR4","first-page":"27","volume":"31","author":"D Hern\u00e1ndez","year":"2011","unstructured":"Hern\u00e1ndez D, Hern\u00e1ndez D, Mart\u00ednez D, Mart\u00ednez D, Guti\u00e9rrez E, Guti\u00e9rrez E et al (2011) Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrolog\u00eda (English Edition) 31:27\u201334","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"3754_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrneph.2009.113","volume":"5","author":"C Li","year":"2009","unstructured":"Li C, Yang CW (2009) The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 5:513\u2013519","journal-title":"Nat Rev Nephrol"},{"key":"3754_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/TP.0b013e3181a059a1","volume":"87","author":"SM Flechner","year":"2009","unstructured":"Flechner SM (2009) Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 87:S1\u2013S6","journal-title":"Transplantation"},{"key":"3754_CR7","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/j.1600-6143.2011.03713.x","volume":"11","author":"S Lodhi","year":"2011","unstructured":"Lodhi S, Lamb K, Meier-Kriesche HU (2011) Improving long-term outcomes for transplant patients: Making the case for long-term disease-specific and multidisciplinary research. Am J Transplant 11:2264\u20132265","journal-title":"Am J Transplant"},{"key":"3754_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","volume":"89","author":"L Gullestad","year":"2010","unstructured":"Gullestad L, Iversen M, Mortensen S-A, Eiskj\u00e6r H, Riise GC, Mared L et al (2010) Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 89:864\u2013872","journal-title":"Transplantation"},{"key":"3754_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ki.2013.253","volume":"85","author":"J-E Serre","year":"2014","unstructured":"Serre J-E, Michonneau D, Bachy E, No\u00ebl L-H, Dubois V, Suberbielle C et al (2014) Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int 85:182\u2013190","journal-title":"Kidney Int"},{"key":"3754_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijcard.2013.11.036","volume":"171","author":"F Gonzalez-Vilchez","year":"2014","unstructured":"Gonzalez-Vilchez F, de Prada JV, Paniagua M, Gomez-Bueno M, Arizon J, Almenar L et al (2014) Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int J Cardiol 171:15\u201323","journal-title":"Int J Cardiol"},{"key":"3754_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:1\u201313","journal-title":"Clin Dev Immunol"},{"key":"3754_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","volume":"27","author":"VR Peddi","year":"2013","unstructured":"Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev 27:97\u2013107","journal-title":"Transplant Rev"},{"key":"3754_CR13","first-page":"133","volume":"23","author":"L Rostaing","year":"2010","unstructured":"Rostaing L, Kamar N (2010) mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23:133\u2013142","journal-title":"J Nephrol"},{"key":"3754_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/petr.12147","volume":"17","author":"R Ganschow","year":"2013","unstructured":"Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P et al (2013) Growing experience with m TOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant 17:694\u2013706","journal-title":"Pediatr Transplant"},{"key":"3754_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ki.2010.492","volume":"79","author":"MR Weir","year":"2011","unstructured":"Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D et al (2011) Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 79:897\u2013907","journal-title":"Kidney Int"},{"key":"3754_CR16","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","volume":"12","author":"L Mj\u00f6rnstedt","year":"2012","unstructured":"Mj\u00f6rnstedt L, S\u00f8rensen SS, von Zur M\u00fchlen B, Jespersen B, Hansen J, Bistrup C et al (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12:2744\u20132753","journal-title":"Am J Transplant"},{"key":"3754_CR17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","volume":"92","author":"RL Heilman","year":"2011","unstructured":"Heilman RL, Younan K, Wadei HM, Mai ML, Reddy KS, Chakkera HA et al (2011) Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 92:767\u2013773","journal-title":"Transplantation"},{"key":"3754_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U et al (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837\u2013847","journal-title":"Lancet"},{"key":"3754_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","volume":"90","author":"M Guba","year":"2010","unstructured":"Guba M, Pratschke J, Hugo C, Kr\u00e4mer BK, Nohr-Westphal C, Brockmann J et al (2010) Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 90:175\u2013183","journal-title":"Transplantation"},{"key":"3754_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","volume":"95","author":"D Cibrik","year":"2013","unstructured":"Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG et al (2013) Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 95:933\u2013942","journal-title":"Transplantation"},{"key":"3754_CR21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1681\/ASN.2018010009","volume":"29","author":"J Pascual","year":"2018","unstructured":"Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y et al (2018) Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 29:1979\u20131991","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3754_CR22","doi-asserted-by":"publisher","first-page":"e0104922","DOI":"10.1128\/mbio.01049-22","volume":"13","author":"MJ Hoy","year":"2022","unstructured":"Hoy MJ et al (2022) Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against cryptococcus. MBio 13(3):e0104922","journal-title":"MBio"},{"issue":"10","key":"3754_CR23","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2004-10-3927","volume":"105","author":"YR Lee","year":"2005","unstructured":"Lee YR et al (2005) Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105(10):3951\u20133955","journal-title":"Blood"},{"key":"3754_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.compbiolchem.2017.06.004","volume":"70","author":"S Shityakov","year":"2017","unstructured":"Shityakov S et al (2017) In silico investigation of propofol binding sites in human serum albumin using explicit and implicit solvation models. Comput Biol Chem 70:191\u2013197","journal-title":"Comput Biol Chem"},{"issue":"40","key":"3754_CR25","doi-asserted-by":"publisher","first-page":"25543","DOI":"10.1021\/acsomega.0c01295","volume":"5","author":"S Shityakov","year":"2020","unstructured":"Shityakov S et al (2020) Novel approach for characterizing propofol binding affinities to serum albumins from different species. ACS Omega 5(40):25543\u201325551","journal-title":"ACS Omega"},{"key":"3754_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3389\/fchem.2019.00920","volume":"7","author":"E Sarukhanyan","year":"2019","unstructured":"Sarukhanyan E et al (2019) Rational drug design of Axl tyrosine kinase type i inhibitors as promising candidates against cancer. Front Chem 7:920","journal-title":"Front Chem"},{"key":"3754_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.736509","volume":"9","author":"S Shityakov","year":"2021","unstructured":"Shityakov S et al (2021) Scaffold searching of FDA and EMA-approved drugs identifies lead candidates for drug repurposing in Alzheimer\u2019s disease. Front Chem 9:736509","journal-title":"Front Chem"},{"key":"3754_CR28","doi-asserted-by":"crossref","unstructured":"Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668\u20131688","DOI":"10.1002\/jcc.20290"},{"issue":"8","key":"3754_CR29","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1021\/acs.jcim.9b00439","volume":"59","author":"R Galvelis","year":"2019","unstructured":"Galvelis R et al (2019) A scalable molecular force field parameterization method based on density functional theory and quantum-level machine learning. J Chem Inf Model 59(8):3485\u20133493","journal-title":"J Chem Inf Model"},{"key":"3754_CR30","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577\u20138593","journal-title":"J Chem Phys"},{"key":"3754_CR31","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/jcc.540130805","volume":"13","author":"S Miyamoto","year":"1992","unstructured":"Miyamoto S, Kollman PA (1992) Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 13:952\u2013962","journal-title":"J Comput Chem"},{"key":"3754_CR32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/ar000033j","volume":"33","author":"PA Kollman","year":"2000","unstructured":"Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L et al (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889\u2013897","journal-title":"Acc Chem Res"},{"issue":"Suppl 1","key":"3754_CR33","first-page":"5","volume":"4","author":"F Diekmann","year":"2015","unstructured":"Diekmann F, Campistol JM (2015) Practical considerations for the use of mTOR inhibitors. Transplant Res 4(Suppl 1):5","journal-title":"Transplant Res"},{"issue":"3","key":"3754_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/ajt.12572","volume":"14","author":"AI Sutherland","year":"2014","unstructured":"Sutherland AI, Akhtar MZ, Zilvetti M, Brockmann J, Ruse S, Fuggle SV et al (2014) Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. Am J Transpl 14(3):677\u2013684","journal-title":"Am J Transpl"},{"key":"3754_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.547849","volume":"8","author":"I Legaz","year":"2021","unstructured":"Legaz I et al (2021) PCR array technology in biopsy samples identifies up-regulated mTOR Pathway genes as potential rejection biomarkers after kidney transplantation. Front Med (Lausanne) 8:547849","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3754_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jcc.10379","volume":"25","author":"H Gohlke","year":"2004","unstructured":"Gohlke H, Case DA (2004) Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. J Comput Chem 25(2):238\u2013250","journal-title":"J Comput Chem"},{"key":"3754_CR37","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1111\/ajt.12481","volume":"13","author":"H Silva Jr","year":"2013","unstructured":"Silva H Jr, Felipe CR, Garcia V, Neto E, Filho M, Contieri F et al (2013) Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 13:3155\u20133163","journal-title":"Am J Transplant"},{"key":"3754_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/TP.0b013e3181963371","volume":"87","author":"J Groetzner","year":"2009","unstructured":"Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T et al (2009) Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87:726\u2013733","journal-title":"Transplantation"},{"key":"3754_CR39","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","volume":"9","author":"Y Lebranchu","year":"2009","unstructured":"Lebranchu Y, Thierry A, Toupance O, Westeel P, Etienne I, Thervet E et al (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115\u20131123","journal-title":"Am J Transplant"},{"key":"3754_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663602","volume":"12","author":"J Zeng","year":"2021","unstructured":"Zeng J et al (2021) Conversion from calcineurin inhibitors to mammalian target of rapamycin inhibitors in kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Front Immunol 12:663602","journal-title":"Front Immunol"},{"key":"3754_CR41","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1523-1755.2005.00472.x","volume":"68","author":"S Lamas","year":"2005","unstructured":"Lamas S (2005) Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 68:898","journal-title":"Kidney Int"},{"key":"3754_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00007890-198608000-00010","volume":"42","author":"AC Novick","year":"1989","unstructured":"Novick AC et al (1989) Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 42:154","journal-title":"Transplantation"},{"key":"3754_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","volume":"321","author":"BD Kahan","year":"1989","unstructured":"Kahan BD (1989) Cyclosporine. N Engl J Med 321:1725","journal-title":"N Engl J Med"},{"key":"3754_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.humimm.2018.04.002","volume":"79","author":"PC Grenzi","year":"2018","unstructured":"Grenzi PC, Campos EF, Tedesco-Silva H Jr, Felipe CR, Soares MF, Medina-Pestana J et al (2018) Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients. Hum Immunol 79:550\u2013557","journal-title":"Hum Immunol"},{"key":"3754_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-1440-2-S1-S3","volume":"2","author":"P Gatault","year":"2013","unstructured":"Gatault P, Lebranchu Y (2013) Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? Transplant Res 2:1\u20137","journal-title":"Transplant Res"},{"key":"3754_CR46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.healun.2012.11.028","volume":"32","author":"I Kaczmarek","year":"2013","unstructured":"Kaczmarek I, Zaruba M-M, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C et al (2013) Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus\/mycophenolate mofetil) after heart transplantation: 5-year results. J Heart Lung Transplant 32:277\u2013284","journal-title":"J Heart Lung Transplant"},{"key":"3754_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11538530-000000000-00000","volume":"13","author":"B H\u00f6cker","year":"2011","unstructured":"H\u00f6cker B, T\u00f6nshoff B (2011) Calcineurin Inhibitor-Free Immunosuppression in Pediatric Renal Transplantation. Pediatr Drugs 13:49\u201369","journal-title":"Pediatr Drugs"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03754-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T16:09:11Z","timestamp":1709914151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03754-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["3754"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03754-3","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}